

## Neurotech to present at NWR Virtual Healthcare Conference

**Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”)**, a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO & Managing Director Dr Anthony Filippis will present at **1:30pm AEDT on Wednesday 25 March 2026**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: [https://us02web.zoom.us/webinar/register/WN\\_Gfml4rppTCC1Crf\\_Ev43BQ](https://us02web.zoom.us/webinar/register/WN_Gfml4rppTCC1Crf_Ev43BQ)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please visit: <https://nwrcommunications.com/healthconf>

### Authority

This announcement was authorised for release by Anthony Filippis, Managing Director and CEO of Neurotech International Limited.

For further information contact us via [info@neurotechinternational.com](mailto:info@neurotechinternational.com)

### About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.